Capricor Therapeutics (Capricor Therapeutics) EV-to-Revenue : 5.15 (As of May. 13, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Capricor Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Capricor Therapeutics's enterprise value is $129.71 Mil. Capricor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $25.18 Mil. Therefore, Capricor Therapeutics's EV-to-Revenue for today is 5.15.

The historical rank and industry rank for Capricor Therapeutics's EV-to-Revenue or its related term are showing as below:

CAPR' s EV-to-Revenue Range Over the Past 10 Years
Min: -777.56 Med: 14.39 Max: 500.86
Current: 5.15

During the past 13 years, the highest EV-to-Revenue of Capricor Therapeutics was 500.86. The lowest was -777.56. And the median was 14.39.

CAPR's EV-to-Revenue is ranked better than
61.58% of 1036 companies
in the Biotechnology industry
Industry Median: 7.96 vs CAPR: 5.15

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), Capricor Therapeutics's stock price is $5.30. Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.91. Therefore, Capricor Therapeutics's PS Ratio for today is 5.84.

Capricor Therapeutics EV-to-Revenue Historical Data

The historical data trend for Capricor Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics EV-to-Revenue Chart

Capricor Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

-3.18

123.33

158.56

22.96

4.57

Capricor Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															22.96	11.52	9.26	4.44	4.57

Competitive Comparison of Capricor Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Capricor Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's EV-to-Revenue falls into.

Capricor Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Capricor Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	129.714	/	25.178
	=	5.15

Capricor Therapeutics's current Enterprise Value is $129.71 Mil.
Capricor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.18 Mil.

Capricor Therapeutics (NAS:CAPR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Capricor Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	5.30	/	0.907
	=	5.84

Capricor Therapeutics's share price for today is $5.30.
Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.91.

Capricor Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics (Capricor Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (NAS:CAPR) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

4LN2:Germany

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Executives

David B Musket	director	C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paul Gisbert Auwaerter	director	C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Mike Kelliher	director	C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Philip J Gotwals	director	C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Xavier Avat	officer: CHIEF BUSINESS OFFICER	10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Karimah Es Sabar	director	C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211
Linda Marban	director, officer: CHIEF EXECUTIVE OFFICER	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Dunbar George W Jr	director	C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825
Karen Krasney	officer: EVP, GENERAL COUNSEL	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Anthony Bergmann	officer: CHIEF FINANCIAL OFFICER	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Louis Manzo	director	C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Cedars Sinai Medical Center	10 percent owner	8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865
St. John Edward A.	10 percent owner	2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244
Leland Gershell	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022